In an in vivo model of non-alcoholic fatty liver disease (NAFLD), aucubin ameliorated tyloxapol-induced hyperlipidemia, oxidative stress, and inflammation by improving lipid profiles (TC, TG, LDL, VLDL) and activating Nrf2, PPARα/γ, HO-1, and AMPK pathways [98]. Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.